Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q3 FY21 results · Oct–Dec 2020
Suven Life Sciences reported revenue from operations of ₹1.51 crore (down 45.4% from Q3 FY20) and net loss of ₹24.39 crore for Q3 FY21 (Oct–Dec 2020), on a consolidated basis.
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.51 | 2.77 | −45.4% | 8.98 | −83.2% |
| Other income | 1.62 | 5.86 | −72.3% | 2.28 | −28.7% |
| Total income | 3.14 | 8.63 | −63.6% | 11.26 | −72.1% |
| Profit before tax | (26.30) | (22.77) | Loss widened | (16.65) | Loss widened |
| Net profit for the period | (24.39) | (22.81) | Loss widened | (15.66) | Loss widened |
| EPS, basic (₹) | (1.92) | (1.79) | Loss widened | (1.23) | Loss widened |
| Net margin (%) | -1612.2 | -822.8 | -174.4 |
| Item | Q3 FY21 | Q3 FY20 | YoY | Q2 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.51 | 2.77 | −45.4% | 8.98 | −83.2% |
| Other income | 1.62 | 5.86 | −72.3% | 2.28 | −28.7% |
| Total income | 3.14 | 8.63 | −63.6% | 11.26 | −72.1% |
| Profit before tax | (10.05) | (4.46) | Loss widened | (2.89) | Loss widened |
| Net profit for the period | (8.15) | (4.50) | Loss widened | (1.90) | Loss widened |
| EPS, basic (₹) | (0.64) | (0.35) | Loss widened | (0.15) | Loss widened |
| Net margin (%) | -538.5 | -162.4 | -21.2 |
Consolidated
- Filed with BSE
- 28 Jan 2021, 18:02 IST
- Board meeting
- 28 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jan 2021, 18:02 IST
- Board meeting
- 28 Jan 2021
- Period
- 01 Oct 2020 to 31 Dec 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE